- Home
- BH vs MLTX Comparison
BH vs MLTX Comparison
Compare BH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BH | MLTX |
|---|---|---|
| Founded | 1934 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BH | MLTX |
|---|---|---|
| Price | $296.56 | $16.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 153.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $597.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $195.05 | $5.95 |
| 52 Week High | $483.60 | $62.75 |
Technical Indicators
Market Signals| Indicator | BH | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.71 | 45.37 |
| Support Level | $269.96 | $14.84 |
| Resistance Level | $319.42 | $19.03 |
| Average True Range (ATR) | 21.72 | 0.73 |
| MACD | -5.12 | -0.22 |
| Stochastic Oscillator | 5.46 | 3.72 |
Price Performance
Historical ComparisonAbout BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.